(Q31926146)

5 July 2017

title

Double-blind randomized trial of buprenorphine and methadone in opiate dependence (English)

1 reference

5 July 2017

main subject

randomized experiment

1 reference

1 reference

Petitjean S

1

1 reference

5 July 2017

Stohler R

2

1 reference

5 July 2017

Déglon JJ

3

1 reference

5 July 2017

Livoti S

4

1 reference

5 July 2017

Waldvogel D

5

1 reference

5 July 2017

Uehlinger C

6

1 reference

5 July 2017

Ladewig D

7

1 reference

5 July 2017

publication date

1 March 2001

1 reference

Drug and Alcohol Dependence

5 July 2017

published in

1 reference

5 July 2017

volume

62

1 reference

5 July 2017

issue

1

1 reference

5 July 2017

page(s)

97-104

1 reference

Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans

5 July 2017

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Plasma concentrations of buprenorphine 24 to 72 hours after dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Buprenorphine versus methadone maintenance for the treatment of opioid dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

1 reference

7 January 2021

A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Six deaths linked to concomitant use of buprenorphine and benzodiazepines

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Buprenorphine responders: A diagnostic subgroup of heroin addicts?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Comparison of buprenorphine and methadone in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900163-0

7 January 2021

10.1016/S0376-8716(00)00163-0

Identifiers

DOI

1 reference

5 July 2017

1 reference